Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease.
D000818:Animals; D000927:Anticonvulsants / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D000978:Antiparkinson Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D015306:Biogenic Monoamines / Q000378:metabolism; D020747:Calcium Channels, T-Type / Q000096:biosynthesis; D006801:Humans; D007555:Isoxazoles / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D018696:Neuroprotective Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D018384:Oxidative Stress; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D000078305:Zonisamide
D000927:Anticonvulsants; D000978:Antiparkinson Agents; D015306:Biogenic Monoamines; D020747:Calcium Channels, T-Type; D007555:Isoxazoles; D018696:Neuroprotective Agents; D000078305:Zonisamide